Clinical Trial Update: Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

This Phase 3 trial compared pemetrexed disodium with erlotinib hydrochloride as second-line therapy for advanced non-small cell lung cancer. The study was termi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Erlotinib hydrochloride (Erlotinib)
• Pemetrexed disodium (Pemetrexed disodium)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer | Phase 3 | Status: TERMINATED | Results posted: 2014-10-02